REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jan 14, 2013--EndoGastric Solutions®(EGS), the leader in endoluminal treatment of Gastroesophageal Reflux Disease (GERD), today announced two additions to the company’s management team—Pat Crilly, PsyD as Vice President, Human Asset Development and Lilip Lau as Senior Vice President, Research and Development.
“We have restructured our management team to enhance our efforts in clinical research and product development, and building deeper relationships with existing customers. Pat Crilly and Lilip Lau are excellent additions to our management team,” said Mike Kleine, President and CEO of EGS. “Mr. Lau has rich experience leading research and development; his expertise will be critical to continued innovation of our technology and furthering the science of transoral procedures. As head of sales and human resources, Dr. Crilly will help the organization fortify relationships with key stakeholders.” Prior to EGS, Dr. Crilly was President of Performance Solutions International, Inc., a consultancy focused on human asset development, sales leadership and market planning strategy. Past leadership roles include Director of International Strategic Marketing at Hoffman La Roche, Vice President of Human Asset Development at the Masimo Corporation, Vice President of Global Sales and Marketing at Johnson & Johnson, Vice President of Global Sales and Marketing at Hybritech/Eli Lilly, and Vice President of Human Asset Development at Biosensor. Dr. Crilly holds a Bachelor of Science from Stockton State College, and both a Master of Science in Behavioral Psychology and a Doctor of Psychology from California Coast University.
Mr. Lau began his career as an engineer at Advanced Cardiovascular Systems (ACS), formerly a division of Guidant and now a part of Abbott Vascular. While at ACS, Mr. Lau invented and patented the Multi-Link stent design and rapid exchange delivery that became the foundation of the Abbott stent franchise. These products, the best-selling stent platform in history, have been used to treat several million patients and amassed over $5B in sales. Virtually all coronary stents sold in the U.S. today do so under license from the owners of the “Lau” patents.
More recently, Mr. Lau served as Senior Vice President, Chief Technical Officer and Director at Paracor Medical where he led product development and clinical research activities through feasibility clinical trials. Lau was also CEO at CAVU Medical and Vice President of Research and Development at Prograft Medical from inception through acquisition by W.L. Gore and Associates. Mr. Lau holds a Bachelor of Science in Mechanical Engineering from the Massachusetts Institute of Technology and a Master of Science in Mechanical Engineering from Case Western Reserve University. He is listed as an inventor in over 90 issued patents in the U.S.
“EGS remains focused on delivering high-quality customer service, expanding clinical evidence to support transoral procedures, engaging societies and payers on the benefits of our technology, and investing in continued innovation,” concluded Kleine.
About EsophyX ® and Transoral Incisionless Fundoplication (TIF ® ) The EsophyX device was FDA cleared in 2007, and is commercially available in the United States. Inserted transorally with visual guidance from an endoscope, the EsophyX device is used in the TIF procedure to reconstruct the gastroesophageal valve (GEV), restoring its competency and reestablishing the barrier to reflux. TIF is a surgical solution that corrects the root cause of Gastroesophageal Reflux Disease (GERD), a disease that affects over 60 million people in the U.S. Because TIF is rooted in traditional surgical principles and is minimally invasive, the procedure offers similar effectiveness to a surgical repair with the safety profile of a transoral approach. To date, more than 10,000 patients have been treated worldwide.
About EndoGastric Solutions ® EndoGastric Solutions, Inc. (www.endogastricsolutions.com), headquartered in Redwood City, California, is a leader in the endoluminal treatment of digestive diseases. EGS' mission is to utilize the most current wisdom in gastroenterology and surgery to develop procedures and products that address unmet needs in gastrointestinal diseases.CONTACT: EndoGastric Solutions, Inc.
Josh DeFonzo, 650-220-2220 email@example.com www.endogastricsolutions.com www.GERDHelp.com KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: SURGERY HEALTH BIOTECHNOLOGY CLINICAL TRIALS MEDICAL DEVICES SOURCE: EndoGastric Solutions Copyright Business Wire 2013 PUB: 01/14/2013 09:00 AM/DISC: 01/14/2013 09:00 AM http://www.businesswire.com/news/home/20130114005143/